Q1
– $12.75M Series A funding
Q2
– IND filed for Phase 1/2a study to evaluate RM-1929 in Recurrent HNSCC in US
2018.02.02
Q1
– $12.75M Series A funding
Q2
– IND filed for Phase 1/2a study to evaluate RM-1929 in Recurrent HNSCC in US
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
© Rakuten Medical Inc. 2022, All rights reserved.